Frontiers in allergy最新文献

{"title":"Clinical characteristics of Netherton syndrome and exploration of targeted biologic therapy: two case reports.","authors":"Wanyan Xiang, Chengxiang Lian, Jiarong Lu, Wenjun Zheng, Qiuju Li","doi":"10.3389/falgy.2025.1667357","DOIUrl":"10.3389/falgy.2025.1667357","url":null,"abstract":"<p><strong>Background: </strong>Netherton syndrome (NS) is a rare, autosomal recessive disease resulting from a mutation in the pathogenic variants in the Kazal type 5 (SPINK5) gene. In recent years, the targeted treatment of biological agents has increasingly emerged as a focal point of research.</p><p><strong>Case reports: </strong>We reported a 4-month-old child and 19-year-old female, both presenting with symptoms including erythema, scaling, and recurring episodes. Subsequently, genetic testing identified a defective SPINK5 gene, leading to a diagnosis of NS. The child received treatment with dupilumab, while the 19-year-old woman alternated between using dupilumab and secukinumab. Both patients had swift and enduring enhancement of skin lesions during the follow-up period.</p><p><strong>Conclusion: </strong>NS is an uncommon and frequently misdiagnosed hereditary dermatological disease. The management strategies for this condition are diverse, and no consensus exists. We implemented various biologic regimens for distinct patients, all demonstrating favorable outcomes and satisfactory tolerance. Besides, monitoring and evaluating the long-term safety of biologics in combination is essential.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1667357"},"PeriodicalIF":3.1,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12441801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical features, pathophysiological mechanisms, and multidisciplinary management strategies for rhinitis-induced adenoid facies in children and adolescents: a review.","authors":"Ying Ding, Yan Xu, Shanshan Han, Min Gao, Long Wang, Shanshan Xu, Ting Guo, Huiwen Bai","doi":"10.3389/falgy.2025.1650119","DOIUrl":"10.3389/falgy.2025.1650119","url":null,"abstract":"&lt;p&gt;&lt;p&gt;Chronic rhinitis and its associated persistent nasal obstruction and mouth breathing are core factors leading to the development of characteristic \"rhinitis face\" or \"adenoid facies\" in children and adolescents. This review elucidates the diverse clinical manifestations of \"rhinitis face,\" including: persistent open-mouth posture; abnormal patterns of facial skeletal growth, such as midface hypoplasia and increased lower anterior facial height resulting in \"long face syndrome\"; alterations in jaw morphology and position, including maxillary constriction, high-arched palate, and mandibular retrognathia or posterior-inferior rotation; and various dentoalveolar malocclusions, such as proclined maxillary incisors, lip incompetence, narrow dental arches, and open bite. Additionally, these include characteristic periorbital skin changes, such as \"allergic shiners\" (dark circles under the eyes due to venous stasis or pigmentation), Dennie-Morgan lines (infraorbital folds associated with atopy), and, in some patients, eyelash trichomegaly (increased eyelash growth) potentially due to chronic inflammation. The nose may also exhibit a transverse nasal crease (the \"allergic salute\" sign) from repetitive rubbing. This paper delves into its pathophysiological mechanisms, emphasizing that mouth breathing patterns triggered by chronic nasal airway obstruction are the initiating factor. This alters the equilibrium of orofacial muscle forces, interferes with normal tongue posture and function, and affects the normal growth trajectory of the maxillofacial skeleton. Combined with local inflammatory responses and mechanical stimuli, these factors collectively contribute to the development of these complex facial characteristics. Clinical assessment requires a comprehensive approach including medical history, detailed physical examination, and various ancillary investigations such as nasal endoscopy, imaging studies (x-ray, CT, CBCT), cephalometric analysis, nasal patency tests, and allergen testing. \"Rhinitis face\" not only affects aesthetics but can also lead to severe maxillofacial skeletal deformities, dental malocclusions, temporomandibular joint dysfunction, and sleep-disordered breathing. It can also profoundly impact respiratory physiology, exercise tolerance, speech clarity, psychological well-being, and quality of life. Its long-term effects can persist into adulthood, although skeletal adaptive changes diminish after growth cessation. Regarding gender differences in its prevalence, existing data suggest that upstream factors (such as obstructive sleep apnea) may have a higher prevalence in males, and the impact of mouth breathing on facial morphology might exhibit sex-specific differences. However, the overall sex ratio for \"rhinitis face\" remains inconclusive. Concerning the notion that rhinitis causes enlarged eyes, there is currently no scientific evidence to support an actual increase in eyeball size. The perception of \"larger eyes\" is more likel","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1650119"},"PeriodicalIF":3.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12436496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145082606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: The advance on pathophysiological mechanisms of type 2 chronic rhinosinusitis with nasal polyposis.","authors":"Cheng Yang, Ling Guo, Yuhan Wang, Wenjing Jiang, Sijia Chen, Qingjia Gu","doi":"10.3389/falgy.2025.1679519","DOIUrl":"https://doi.org/10.3389/falgy.2025.1679519","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/falgy.2025.1599797.].</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1679519"},"PeriodicalIF":3.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145082617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of shrimp allergy: a meta-analysis based on different diagnostic methods.","authors":"Jiaqi Chen, Qiang Zhang, Yongli Ying, Xuying Zhang, Chunsheng Qu","doi":"10.3389/falgy.2025.1635274","DOIUrl":"10.3389/falgy.2025.1635274","url":null,"abstract":"<p><strong>Background: </strong>Shrimp allergy (SA) represents a significant public health concern, yet its overall prevalence remains unclear.</p><p><strong>Method: </strong>A systematic search of PubMed, Web of Science, and Embase through September 30, 2024 identified 40 studies that reported SA prevalence using self-reported symptoms, physician diagnosis, skin prick tests, specific IgE, or food challenge tests.</p><p><strong>Results: </strong>The pooled prevalence was estimated at 1.90% for self-reported symptomatic SA and 1.94% for self-reported physician-diagnosed SA, while testing via skin prick or specific IgE yielded a prevalence of 2.76%. Notably, symptomatic testing showed a lower prevalence of 0.43%, and food challenge tests confirmed a prevalence of 0.50%. Considerable heterogeneity was observed across studies, with prevalence varying by region and age group, and no publication bias was detected.</p><p><strong>Conclusion: </strong>These findings indicate that the prevalence of SA varies with diagnostic criteria, age, and region, underscoring the need for harmonized diagnostic standards to improve prevalence estimates and guide public health strategies.</p><p><strong>Systematic review registration: </strong>identifier [CRD420251003956].</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1635274"},"PeriodicalIF":3.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12434110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145076665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modulation of allergic airways disease employing bio-mimetic nanoparticles with TLR agonists.","authors":"Melanie Cristine Scalise, Seyran Mutlu, Céline Ferrié, Mario Amacker, Christophe von Garnier, Philip Stumbles, Fabian Blank","doi":"10.3389/falgy.2025.1633293","DOIUrl":"10.3389/falgy.2025.1633293","url":null,"abstract":"<p><strong>Introduction: </strong>Allergic asthma is characterized by airway hyperresponsiveness due to a biased Th2 immune response against harmless environmental substances. While most current treatments alleviate symptoms without altering the disease's progression, allergen-specific immunotherapy (AIT) is the only clinically approved strategy known to modify the natural course of allergic disease. However, AIT has limitations, highlighting the need for improved formulations that provide safer, faster, and more effective immune modulation.</p><p><strong>Methods: </strong>In this study, we designed bio-mimetic nanoparticles and evaluated their effects in a mouse model of experimental allergic inflammatory airways disease (EAIAD). Mice were sensitized with ovalbumin (OVA) and treated with liposomes or virosomes conjugated with OVA and the TLR7/8 agonist 3M-052. Lung function, inflammatory cell recruitment, cytokine profiles, and immunoglobulin levels were analyzed post-treatment.</p><p><strong>Results: </strong>Among the tested formulations, liposomes co-delivering OVA and 3M-052 (Lipo-OVA) led to partial improvements in lung mechanics, including lower airway resistance (Rrs) and preserved forced expiratory volume (FEV0.1). Immune profiling revealed formulation-specific effects on eosinophil and macrophage populations, and modest shifts in cytokine secretion patterns. However, no formulation fully resolved airway inflammation or significantly reduced Th2 cytokines or total IgE levels.</p><p><strong>Discussion: </strong>These findings support the feasibility of nanoparticle-based AIT strategies, while also highlighting the need for further optimization to enhance efficacy, minimize sensitization, and promote sustained long-term immune tolerance.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1633293"},"PeriodicalIF":3.1,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12426108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145066577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acoustic therapy for allergic rhinitis and chronic rhinosinusitis: modulating microbiome, immunity and well-being.","authors":"Jude Oluwapelumi Alao, Kelvin E M Lau, David White, Kevin Lee, Chris Puli'uvea, Jim Bartley","doi":"10.3389/falgy.2025.1649031","DOIUrl":"10.3389/falgy.2025.1649031","url":null,"abstract":"<p><p>Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) are common respiratory conditions that significantly impact patient health and contribute to substantial healthcare burdens. While conventional treatments offer symptom relief, many patients continue to experience persistent symptoms, side effects, or resistance to standard therapies. This highlights the growing need for novel, non-invasive, and sustainable therapeutic strategies to manage chronic airway inflammation. This review examines acoustic therapy, an emerging non-pharmacological treatment that uses sound wave-induced vibrations as a potential adjunctive therapy for AR and CRS. Acoustic therapy shows potential benefits, including enhanced nitric oxide production, improved mucociliary clearance, and modulation of immune responses by activating mechanosensitive pathways and disrupting pathogenic biofilms. Preliminary clinical findings across some trials have reported improvements in peak nasal inspiratory flow ranging from approximately 17% to 31%, significant reductions in nasal congestion and symptom scores, such as Total Nasal Symptom Score, Sino-Nasal Outcome Test-22 (SNOT-22), and enhancements in sleep quality and patient-reported outcomes. Given this limited but expanding body of evidence, we integrate interdisciplinary insights from respiratory medicine, immunology, and microbiome science to provide a translational framework for future research. We highlight the need for rigorously designed clinical trials to assess acoustic therapy's therapeutic efficacy, safety, and long-term impact. As this field evolves, acoustic therapy holds significant potential to address unmet needs in chronic respiratory diseases and contributes to improved patient care.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1649031"},"PeriodicalIF":3.1,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12415040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145031246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical, functional, and laboratory course of children and adolescents with severe asthma after discontinuation of biologics.","authors":"Valentina Agnese Ferraro, Raimondo Junior Castaldo, Fiorenza Alfier, Margherita Amadi, Chiara Pertoldi, Valentina Tonazzo, Stefania Zanconato, Silvia Carraro","doi":"10.3389/falgy.2025.1672424","DOIUrl":"10.3389/falgy.2025.1672424","url":null,"abstract":"<p><strong>Background: </strong>Although the benefits of biologics in severe asthma are well established, the optimal strategy to discontinue therapy remains controversial.</p><p><strong>Aim: </strong>to evaluate clinical, functional, and laboratory course of children and adolescents with severe asthma after biological therapy withdrawal due to sustained good control. Secondary aim was to identify clinical or inflammatory markers predictive of asthma control after discontinuation.</p><p><strong>Materials and methods: </strong>this retrospective study included patients 6-19 years with severe asthma followed at the University Hospital of Padua in whom a biologic therapy was discontinued after at least 24 months of treatment. Clinical (GINA, CASI, exacerbations), functional (spirometry), inflammatory (FeNO, IgE, eosinophils), pharmacological (ICS dosage), and quality-of-life (PAQLQ) data were collected over a 24-month follow-up.</p><p><strong>Results: </strong>twenty-three asthmatic patients (34.8% female) were included. 19 treated with Omalizumab, 3 Dupilumab, and 1 Mepolizumab. At withdrawal, all had well-controlled asthma (GINA and CASI 3). Clinical control scores, spirometry, PAQLQ remained stable overtime. No exacerbation increase was observed. One patient resumed biologic therapy. An increase in eosinophil counts was found in patients classified as not fully controlled at 24 months.</p><p><strong>Conclusions: </strong>clinical and functional benefit of biologics may persist for up to 24 months after biologic withdrawal. After biologic discontinuation, most children maintained symptom control and good quality of life, suggesting that biologic therapy may be stopped in appropriately selected cases. At the same time a close follow-up, including assessment of clinical control, functional parameter and biomarkers, is needed to promptly identify signs associated with possible loss of control.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1672424"},"PeriodicalIF":3.1,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411174/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145016761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-year real-life outcomes of lanadelumab therapy in Romanian patients with hereditary angioedema due to C1-inhibitor deficiency.","authors":"Noémi Anna Bara, Valentin Nădășan, Diana Deleanu","doi":"10.3389/falgy.2025.1636425","DOIUrl":"10.3389/falgy.2025.1636425","url":null,"abstract":"<p><strong>Introduction: </strong>In the majority of patients with hereditary angioedema (HAE) due to C1-inhibitor deficiency (HAE-C1INH), effective long-term prophylactic (LTP) treatment can achieve complete disease control. Lanadelumab is one of the first-line option recommended for this purpose. Our study aimed to evaluate changes in disease control, quality of life, and attack frequency among Romanian HAE-C1INH patients, during the first year of treatment with lanadelumab.</p><p><strong>Methods: </strong>This non-interventional prospective study included the Romanian HAE-C1INH patients enrolled in the first year of the national lanadelumab treatment program. Angioedema Control Test, (AECT), Angioedema Quality of Life Questionnaire (AE-QoL) and attacks frequency were recorded at baseline and at 3, 6, 9 and 12 months.</p><p><strong>Results: </strong>Twenty-four patients (14 women [58.3%], 10 men [41.7%]) initiated lanadelumab therapy, with a mean age of 40.7 years. Most had HAE-C1INH type I (22 patients, 91.7%), and one patient was under 18 years of age. Ten patients switched from LTP with intravenous plasma-derived C1-INH, while 14 were previously managed with on-demand therapy only. Baseline scores were: AECT 4.5 [interquartile range (IQR) 2.0], AE-QoL 66.1 [standard deviation (SD) 18.3], and a mean attack frequency of 10.0 (IQR 4.0) (over the preceding three months). Improvements were observed at each follow-up point, with respective scores at 3, 6, 9 and 12 months as follows: three months: AECT 12.0 (IQR 5.8) / AE-QoL 35.3 (SD 23.2)/ attacks 3.4 (IQR 5.0); six months: AECT 12.3 (IQR 5.3) / AE-QoL 35.4 (SD 25.4)/ attacks 2.8 (IQR 4.8); nine months: AECT 12.6 (IQR 5.8) / AE-QoL 34.1 (SD 23.2)/ attacks 2.2 (IQR 3.8) and 12 months: AECT 12.9 (IQR 5.5) / AE-QoL 32.1 (SD 21.6) / attacks 1.4 (IQR 2.0). Seven patients became symptom-free after the first dose, and four more achieved this status within the first three months.</p><p><strong>Discussion: </strong>LTP with lanadelumab provided effective disease control and significantly improved quality of life in patients with HAE-C1INH over the course of one year. Regular evaluations at relatively short intervals by the availability and ease of administration of validated questionnaires serve as a useful tool for clinicians in the comprehensive assessment of HAE patients and offer a valuable means of monitoring treatment effectiveness.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1636425"},"PeriodicalIF":3.1,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12408505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145016712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mugwort sensitization and asthma as predictors of food-induced anaphylactic shock in children: a retrospective study in Northern China.","authors":"Zibei Zhou, Juan Zhang, Nini Dai, Zailing Li","doi":"10.3389/falgy.2025.1658895","DOIUrl":"10.3389/falgy.2025.1658895","url":null,"abstract":"<p><strong>Introduction: </strong>Food-induced anaphylactic shock is the most severe and life-threatening manifestation of food allergy in children. However, its underlying risk factors remain poorly defined, especially in pediatric populations. This study aimed to identify independent predictors of food-induced anaphylactic shock by analyzing clinical and immunological data from a tertiary hospital in Northern China.</p><p><strong>Methods: </strong>This retrospective study included 68 children (aged 0-16 years) hospitalized for food-induced anaphylaxis at Peking University Third Hospital from May 2018 to May 2025. Demographic data, clinical manifestations, serum-specific immunoglobulin E (sIgE) levels, and comorbidities were collected. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of anaphylactic shock.</p><p><strong>Results: </strong>Of 68 patients with food-induced anaphylaxis, 14 (20.6%) experienced anaphylactic shock, with 78.6% of these cases occurring in children older than six years. Wheat and fruits were the most common triggers in the shock group (each 28.6%). Subgroup analysis revealed that 88.9% (8/9) of plant-food-triggered shock cases specifically clustered from April to October, aligning with mugwort pollen season. sIgE levels to inhalant allergens, especially mugwort, were significantly higher in the shock group (<i>P</i> < 0.05). In multivariate analysis, mugwort sensitization (sIgE levels exceeding 2.83 kU/L, OR = 9.91, 95% CI: 1.27-77.31, <i>P</i> = 0.029) and comorbid asthma (OR = 8.11, 95% CI: 1.29-50.98, <i>P</i> = 0.026) were identified as independent predictors of anaphylactic shock.</p><p><strong>Conclusions: </strong>Mugwort sensitization and asthma are independent risk factors for food-induced anaphylactic shock in children. Early identification of these risk markers may support early risk stratification and seasonal dietary interventions.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1658895"},"PeriodicalIF":3.1,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12408619/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145016726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances of bispecific antibodies using/application in dermatology: a review.","authors":"Ting Zhang, Yang Liu, Pei Xiong Liew, Yu Zhang, Zuotao Zhao","doi":"10.3389/falgy.2025.1668931","DOIUrl":"10.3389/falgy.2025.1668931","url":null,"abstract":"<p><p>Bispecific antibodies represent an important innovation in the field of biomedicine in recent years. Compared to monoclonal antibodies, their specific structure enables a single antibody molecule to bind to two different antigens simultaneously. This characteristic endows bispecific antibodies with more functions, regulating multiple signal pathways simultaneously, enhancing the therapeutic effect, and by infusion of targeted tumor antigens and drug carriers in advance, the contact time between the drug and normal tissues is reduced, and the toxic side effects are greatly reduced. They have shown promising application prospects, especially in dermatology and other fields. This article reviews the basic concepts of bispecific antibodies and their potential application in the treatment of skin diseases, including inflammatory skin diseases, skin tumors, and infectious skin diseases. The aim is to explore the current application status and future development directions of bispecific antibodies in dermatology, so as to provide references for related research and clinical practice.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1668931"},"PeriodicalIF":3.1,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12404918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145002038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}